A Phase 1A/1B, Two-Stage Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA Recurrent Prostate Cancer in Hormone-Naive and Hormone-Independent Patients

Trial Profile

A Phase 1A/1B, Two-Stage Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA Recurrent Prostate Cancer in Hormone-Naive and Hormone-Independent Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs PSA-IL2-GM-CSF vaccine (Primary) ; Interleukin-2
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Acronyms PSA
  • Sponsors Oncobioimune
  • Most Recent Events

    • 02 Jul 2018 According to an OncBioMune Pharmaceuticals media release, company is collecting long-term follow-up results for the 1a portion of this trial.
    • 20 Mar 2018 According to an OncBioMune Pharmaceuticals media release, based upon the impressive body of data from the Phase 1a portion of the study, the company is forgoing the planned 1b portion and moving into two, separate Phase 2 studies of ProscaVax for late-stage (see profile 292849) and early-stage prostate cancer (see profile 261722).
    • 20 Mar 2018 According to an OncBioMune Pharmaceuticals media release, interim data from this trial will be presented at the 2018 American Association for Cancer Research ("AACR") Annual Meeting 2018. The abstract also will be published online in the 2018 Proceedings of the AACR.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top